South African Media Training on Non-Surgical Circumcision Devices

On June 18, AVAC, the Mail & Guardian’s Bhekisisa Centre for Health Journalism and CAPRISA held a media briefing on non-surgical devices for voluntary medical male circumcision (VMMC). This meeting helped contextualize the recent World Health Organization (WHO) prequalification of the PrePex device and took place in advance of the South African AIDS Conference (SAAIDS) in Durban, South Africa.

WHO pre-qualified the PrePex device at the end of May, and this process has generated a lot of interest in devices as potential innovations for VMMC programs. The PrePex device involves two rings: one placed inside the foreskin on the shaft of the penis, and an elastic ring placed over that one that compresses the foreskin, cutting off the blood supply through pressure.

A full house of reporters was present to hear speakers who included Dr. Ntlotleng Mabena of the South African Centre for HIV and Prevention Studies (CHAPS) and Dr. Thobile Mbegnashe of the South African Department of Health. Dr. Mabena reported that CHAPS plans to run a pilot study of the PrePex device—one of several taking place in countries throughout sub-Saharan Africa. Dr. Mbegnashe said that the government would watch this project closely to learn more about PrePex in the South African context. He told the audience that South Africa is committed to ramping up the procedure, with a goal of 4.3 million men circumcised by 2016.

Mia Malan of the Mail & Guardian and founder of the Bhekisisa Centre wrote a great piece about PrePex and VMMC in South Africa.

Press Release

WHO prequalification of PrePex medical male circumcision device has potential to help countries accelerate key HIV prevention program

New York, NY – The announcement last week that the World Health Organization (WHO) prequalified the PrePex device for non-surgical voluntary medical male circumcision (VMMC) offers another important option for expansion of VMMC programs in countries hard hit by the HIV epidemic. VMMC, as part of comprehensive HIV prevention programs, is starting to make an impact on the HIV epidemic in many communities and countries.

The impact of PrePex, and other non-surgical devices that could also be prequalified, will depend on several factors including the cost of the devices, the quality and scope of data available to guide decisions about product introduction, and sustained investment in product introduction including pilot projects and social marketing.

“PrePex and other devices could help expand VMMC programs to meet the HIV prevention needs of more men in Africa. But without strong programs, even the best products have little or no impact,” said Mitchell Warren, AVAC executive director. “Importantly, WHO’s prequalification paves the way for countries and international donors to procure the device and expand HIV prevention options. Evidence has shown that expanded VMMC programs can have a profound impact on rates of new HIV infections in men and women for years to come.”

“Now, national policy makers, civil society, traditional practitioners, and health providers need to understand the different roles for both surgical and non-surgical procedures and make decisions about whether it makes sense to use PrePex in local programs. If the decision is, ‘yes,’ the product needs to be strategically introduced in programs that have clear messages, committed financing and integration with surgery-based programs. We need action now to ensure these conditions are met,” Warren added.

“For PrePex to make a difference in VMMC scale-up, it has to be affordable,” Warren said. “AVAC and other advocates look forward to working with governments, donors and the manufacturer to help ensure that cost is not a barrier to the use of PrePex where it can make a difference.”

The cost of the device, at least at first, is reported to be around $20, which may be a barrier for widespread use. Bulk purchasing, the prequalification and introduction of additional devices, or a decision by the manufacturer could lead to a lower price. AVAC welcomes today’s statement from UNITAID, which finances the WHO prequalification program, stating that PrePex must be affordably priced.

Landmark clinical trials in three African countries showed that voluntary medical male circumcision (a term used to indicate the specific procedures used in the context of HIV prevention, versus traditional practices in initiation rites) reduced HIV-negative men’s risk of HIV infection by at least 60 percent and long-term follow-up has shown that VMMC is a highly effective and inexpensive intervention.

“International donors have indicated a willingness to fund pilot studies and introduction of PrePex for VMMC programs, but African governments, health care providers and local communities will need to decide how PrePex might best be used to expand VMMC programs. Governments must move swiftly to evaluate whether PrePex is a good additional option and develop policies and budgets to match. Most importantly, governments should continue allocating resources for this HIV prevention strategy overall,” said Angelo Kaggwa, program coordinator at AVAC and a co-coordinator of the Africans Telling the Truth about VMMC campaign.

“This initial prequalification of PrePex is only for men 18 and older. One of the key next steps for PrePex must be to gather data on safety and effectiveness among younger men and adolescents,” Kaggwa added. “Many men seeking surgical procedures are under 18, and we need to provide them with the range of options.”

“WHO prequalification of the PrePex device is most exciting and very welcome. Policy makers, health care providers, donors and civil society must now work together to find the best ways to add non-surgical devices to broader circumcision programs so that we can reach more men with VMMC – with a method that is relatively simple and convenient. I know, because I myself have been circumcised with the PrePex device. So when I add my voice to the PrePex conversations, it is from the perspective of the personal experience of a satisfied client,” said Dr. Mannasseh Phiri, a leading VMMC and HIV/AIDS activist in Zambian. “Circumcision, like HIV, is often difficult for us to discuss openly. And in many of our communities, medical circumcision of adult men is a relatively new concept that now exists alongside traditional circumcisions of young boys. We must continue to speak out about the great benefits of medical male circumcision for men and for women in our communities. We must encourage more and more men of all ages to come forward and get circumcised.”

Current modeling data project that, if 80 percent of adult men in 14 priority African countries (with high HIV incidence and low rates of VMMC) were to undergo the procedure by 2015, 20 percent of all new infections in men and women would be averted by 2025 in those countries. Non-surgical circumcision devices, like PrePex, provide more options to achieve these targets.

WHO prequalification is a process to ensure that medicines, diagnostics and medical devices meet international standards of quality, safety and efficacy. Prequalification helps donors and countries that do not have adequate regulatory capacity to review all products make informed decisions about purchasing medicines and devices. PrePex is the first male circumcision device prequalified by WHO. Other devices are also under development. Manufacturers apply for prequalification and must provide extensive information about the product’s quality, safety and efficacy, which is evaluated by staff from WHO and experts from national regulatory authorities worldwide. More information on devices and the prequalification process is available at www.who.int/diagnostics_laboratory/evaluations/prequalification_status/en/index.html.

For more information on voluntary medical male circumcision, VMMC devices and programs, visit www.avac.org/vmmc, truthaboutvmmc.org and www.malecircumcision.org.

Contact:

Mitchell Warren, mitchell@avac.org, +1-914-661-1536
Kay Marshall, kay@avac.org, +1-347-249-6375

###

About AVAC: Founded in 1995, AVAC is a non-profit organization that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of AIDS vaccines, male circumcision, microbicides, PrEP and other emerging HIV prevention options as part of a comprehensive response to the pandemic.

Achieving the End: One Year and Counting

In AVAC Report 2012, Achieving the End: One Year and Counting we’ve identified five priorities for action.

Achieving the End

Recent breakthroughs in HIV prevention research have created unprecedented opportunities to curb new HIV infections, save lives and set the world on a path towards eliminating HIV transmission.

Cumulative number of male circumcisions performed from 2008 to 2011

From AVAC Report 2012, this graph shows the cumulative number of male circumcisions performed from 2008 to 2011.

Non-Surgical Devices for VMMC

Pictured here, from AVAC Report 2012, is the PrePex device and Shang Ring, two non-surgical devices in development for VMMC.

Reaching the Tipping Point: The time to act is now

AVAC Playbook 2012-2013: Progress toward global goals

AVAC first published its Playbook of global goals for ending AIDS in late 2011. This infographic from the AVAC Report 2012 builds on the objectives from 2011 and identifies five priorities for action in 2013.

Stepping Up the Pace: VMMC accelerates in priority countries

As this graphic from AVAC Report 2012 illustrates, the pace of implementation of VMMC for HIV prevention has increased dramatically since 2010 in priority countries.

The Change We Need to End AIDS in Uganda

2012 AVAC Fellow Alice Kayongo played a leading role in developing a civil society report, “The Change We Need to End AIDS in Uganda”, which details concerns and recommendations for shaping the national AIDS response in Uganda. This report was presented at the Joint Annual Review (JAR) of the country’s five-year National Strategic Plan (NSP) for responding to HIV/AIDS, which was first launched about a year ago. The mid-October JAR meeting was an opportunity to review progress and gaps. In the weeks leading up to the JAR, civil society participated in reviews of draft assessments of progress on the various elements of the NSP, including prevention, treatment and care, and health systems strengthening.

Kayongo was joined in this coalition effort by Sylvia Nakasi and Bharam Namanya of UNASO (2011 Fellow and Host Supervisor, respectively), and Leonard Okello, Alice’s Fellowship supervisor and Lillian Mworeko of ICW-EA (2012 Host)—as well as a broad range of other advocates.

The report, presented at the JAR, included a 10-point plan to halt new infections, save lives and ensure leadership, and provided a detailed critique of the national AIDS response to date.

This advocacy comes on the heels of a dynamic and successful campaign to increase funding for and recruitment of more than 6,000 health care workers throughout Uganda.

For a copy of the report, reach out to fellows@avac.org.